Oekoworld — Normalised revenue and profitability level

Private: ÖKOWORLD (VVV3)

Last close As at 24/04/2024

74.60

1.20 (1.63%)

Market capitalisation

228m

More on this equity

Research: Financials

Oekoworld — Normalised revenue and profitability level

ÖKOWORLD (ÖWAG) reported robust results for H118, recording €7.6m revenues and €2.1m net profit. Even though both measures declined y-o-y by 5.6% and 31.4%, respectively, it is important to note that last year’s figures were particularly strong due to high performance fees driven by favourable equity markets. Fund performance outpaced both the broader market and peers over the long term, but is currently recovering from the Q118 downturn. ÖWAG’s shares trade at a premium to the peer group on P/E and EV/EBITDA for FY18e, which, however, widens in FY19e due to earnings growth expectations below the peer-group average.

Milosz Papst

Written by

Milosz Papst

Director, Financials

Financials

ÖKOWORLD

Normalised revenue and profitability level

Diversified financials

Scale research report - Update

7 September 2018

Price

€17.15

Market cap*

€121m

*Market cap based on 7.06m total shares issued (after deduction of treasury shares); only 3.14m non-voting preference shares listed on the stock market.

Share price graph

Share details

Code

VVV3

Listing

Deutsche Börse Scale

Shares in issue (nonvoting preferred)

3.14m

Last reported net cash as at 30 June 2018

€11.5m

Business description

ÖKOWORLD Group’s business is focused on asset management, insurance brokerage and advisory services. It is one of Germany's pioneers in SRI and ethical-ecological investment advisory, with its nucleus reaching back to 1975. It preserved its successful core investment principles and reached AUM of €1.2bn as at end-June 2018.

Bull

A strong brand with established distribution channels and constant AUM growth

SRI investments have become mainstream with more companies following SRI rules.

Proven track record and numerous awards.

Bear

Despite long history, still relatively low AUM.

Strong dependency on German market.

Only preference shares available to investors.

Analyst

Milosz Papst

+44 (0) 20 3077 5700

ÖKOWORLD (ÖWAG) reported robust results for H118, recording €7.6m revenues and €2.1m net profit. Even though both measures declined y-o-y by 5.6% and 31.4%, respectively, it is important to note that last year’s figures were particularly strong due to high performance fees driven by favourable equity markets. Fund performance outpaced both the broader market and peers over the long term, but is currently recovering from the Q118 downturn. ÖWAG’s shares trade at a premium to the peer group on P/E and EV/EBITDA for FY18e, which, however, widens in FY19e due to earnings growth expectations below the peer-group average.

H118 results confirm long-term growth

The H118 results – €7.6m revenues and €2.1m net profit – exhibit a more normalised level compared with particularly strong performance in FY17, driven by high performance fees. This represents a healthy five-year revenue CAGR at c 10%, driven by both growth in assets under management (AUM) and the positive returns of flagship funds, which outperformed both the broader market and peers over the long term. As at end-June 2018, the company had around €1.2bn AUM (by our calculations) compared with €1.1bn at the end of FY17.

Regaining momentum after a weak Q118

All funds managed by ÖWAG’s 81% subsidiary Ökoworld LUX SA recorded negative returns in the Q118, followed by a slight rebound in the subsequent quarter. However, performance continued to improve beyond H118, with ytd return as at end-August 2018 for the flagship Ökoworld Ökovision Classic fund at 8.9% and favourable exposure to key long-term fundamental themes. Ökoworld Growing Markets 2.0 is still suffering from the recent overall retreat from emerging markets, but the fund managers remain confident in the current portfolio positioning.

Valuation: Still trading at a premium to peers

Following the 36% price rally since the beginning of the year, which was interrupted by a price correction in May, ÖWAG’s shares trade at a premium to the peer group on P/E and EV/EBITDA for FY18e of 28% and 37%, respectively. The premium widens in FY19e due to limited earnings growth expectations (9–10% per annum) as per Bloomberg consensus estimates (however, these are based on estimates from a single broker).

Consensus estimates

Year
end

Revenue
(€m)

PBT
(€m)

EPS
(€)

DPS
(€)

P/E
(x)

Yield
(%)

12/16

9.2

5.2

0.60

0.51

30.6

2.8

12/17

15.8

9.7

1.02

0.59

18.0

3.2

12/18e

19.8

6.4

0.74

0.55

27.8

3.0

12/19e

20.9

7.0

0.81

0.56

25.8

3.1

Source: ÖKOWORLD AG accounts, Bloomberg consensus as at 4 September 2018. Note: Consensus is based on the estimates of a single analyst.

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

Financials: Long-term growth nearing 10% pa

Following the robust performance in FY17 (driven considerably by high performance fees), the H118 results exhibit a more normalised revenue and profitability level. ÖWAG revenues declined 5.6% y-o-y in H118 vs H117, most likely due to the limited performance fees generated in H118 as the company’s funds did not materially surpass their respective high watermarks amid weak equity markets (in particular in Q118). Still, this represents a healthy five-year revenue CAGR at c 10%, driven by both AUM growth and the positive returns of ÖWAG’s flagship funds (ÖKOWORLD ÖKOVISION CLASSIC and ÖKOWORLD GROWING MARKETS 2.0), which outperformed both the broader market and ÖWAG’s peers over the long term (all of the funds under the Ökoworld umbrella are managed by Ökoworld LUX SA, an 81% subsidiary of ÖKOWORLD AG).

On the other hand, operating expenses recorded an increase of 13.1% y-o-y to €4.6m, with the most significant changes in costs of services (15.8% y-o-y) and other operating expenses (24.3% y-o-y). This illustrates the fact that the company’s revenues depend on both the AUM (through the management fee) and managed funds’ performance (through the performance fee), while the costs are connected solely with the overall business size, as measured by the AUM. In the analysed period, the company succeeded in maintaining its AUM growth; at 30 June 2018, it had around €1.2bn AUM (according to our calculations) compared with €1.1bn at the end of FY17.

This resulted in an EBIT and net income decline of c 25% and 31% y-o-y, respectively, and a margin compression of more than 10pp. Looking at the H118 results in the context of H116 numbers, however, ÖWAG recorded a two-year CAGR of 30.5% in EBIT, 28.7% in EBT and 14.1% in net profit, confirming the steady business improvement. This reflects the business growth over this period (AUM in H116 stood at around €0.8bn).

Exhibit 1: H118 results highlights

€000s

H118

H117

H116

Total revenue

7,604

8,059

3,950

Costs of services

(2,053)

(1,773)

(2166)

Personnel expenses

(1,444)

(1,413)

(847)

Other operating expenses

(1,057)

(850)

(691)

D&A

(88)

(68)

(67)

Income from related companies

0

0

1,560

EBIT

2,963

3,955

1,740

EBIT margin

39.0%

49.1%

44.0%

Other interest and similar income

2

6

44

Interest and similar expenses

(11)

(2)

(1)

EBT

2,954

3,959

1,782

EBT margin

38.8%

49.1%

45.1%

Income tax

(885)

(944)

(193)

effective tax rate

30.0%

23.9%

10.8%

Net profit for the period

2,069

3,015

1,589

Net income margin

27.2%

37.4%

40.2%

Source: ÖKOWORLD AG accounts

Post-market correction rebound

The booming market that enabled ÖWAG to post record results in FY17 has cooled down, leaving all its funds with negative returns in Q118, followed by a slight rebound in the subsequent quarter. The flagship fund, ÖKOWORLD ÖKOVISION CLASSIC, which holds 76.5% of all assets under management, recovered from a 3.4% loss in Q118 to post a 3.8% positive return for the first six months of the year and further improved to 8.9% ytd (as at end-August 2018). Consequently, the fund unit price exceeded the previous high watermark, creating some performance fee potential for ÖWAG. These positive results have been recorded despite the company’s more careful stock-picking approach, currently illustrated by the relatively high cash balance (18.6% of asset value as at end-June 2018, up 3.6pp vs end-2017), displaying a potential cash drag effect. The positive returns were driven by successful stock-picking, as the largest sector exposure of the fund – Demography and Medicine (representing 19.4% of assets on average in H118) – generated the highest return at 26.1% until the end of June 2018. This was further assisted by the beneficial exposure to the US dollar (38.7% of total assets at end-June 2018). The US dollar is one of the better-performing currencies ytd, appreciating against the euro by c 4%.

Similar positive results have been recorded by the third-largest fund, ÖKOWORLD ROCK’N’ROLL, which turned the -2.0% loss at the end of Q118 into a 4.3% profit in H118 and 9.4% ytd (as at end-August 2018), also exceeding its previous high watermark. It is the only mixed fund in ÖWAG’s portfolio, but with a significant exposure to equities exceeding 80% of assets as at end-June 2018. Even though the fund’s policy enables the use of derivatives, the fund hedges only shortterm equity risk. Out of the four security classes in which the fund is invested, three have been profitable, with the 12.8% return from shares and minor earnings in annuities and derivatives (only closed-end funds with a main focus on infrastructural projects posted a 4.9% loss).

Among the funds unable to rebound after the Q118 plunge is the ÖKOWORLD GROWING MARKETS 2.0 fund, which recorded a loss in excess of 10% on a ytd basis. The fund employs a different strategy than those previously described, as instead of focusing on the developed markets (for example, the EU emphasis in the case of ROCK’N’ROLL) and thus keeping an exposure to developed currencies, this fund invests in emerging countries. This implies a high exposure to currencies such as the Indian rupee, Brazilian real or South African rand. As a consequence, the fund suffered from the recent overall retreat from emerging markets, with both the MSCI Emerging Markets index and JP Morgan Emerging market currency index posting a visible decline (c -6% and -13% ytd, respectively). This is despite the relatively high exposure to Demography and Medicine themes (in line with ÖKOVISION CLASSIC). Importantly, the investment policy is based on a pure focus on stock-picking rather than pre-defined country/currency exposures and also does not hedge its FX positions (which in this case would have reduced some of the losses). However, the fund managers remain confident that the underlying portfolio holdings exhibit strong fundamentals driven by the long-term themes (millennials, China’s Five-Year Plan, etc).

Exhibit 2: Fund performance and AUM summary

Fund

Ytd return
at end-Aug 2018 (%)

H118
return (%)

Q118
return (%)

2017
return (%)

AUM (€m)
30 June 2018

AUM (€m)
31 Dec 2017

Ökovision Classic

8.9

3.8

(3.4)

11.4

870.1

763.1

Growing Markets 2.0

(10.3)

(7.1)

(4.5)

24.8

149.1

155.3

Rock 'N' Roll

9.4

4.3

(1.9)

13.7

60.8

50.2

Klima

9.0

5.6

(1.1)

21.1

36.4

28.0

Water for Life

1.9

(1.0)

(4.7)

15.4

20.5

19.9

Source: ÖKOWORLD AG

Valuation

ÖWAG’s market cap is c €121m and its enterprise value (EV) stands at c €133m. The company had c €1.2bn in AUM at the end of June 2018 and achieved a return on equity of 36% in H118 (although this was somewhat inflated by non-recurring effects).

Selecting a peer group for the valuation purposes appears to be difficult, as the market lacks directly comparable business models. The asset management units are rarely listed, while the funds are listed and trade around NAV. Companies with both business structures might include:

Patrizia Immobilien (real estate asset management in separate funds, asset structuring and advisory);

MLP (an insurance broker and asset advisory, running its own fund group);

IMPAX Asset Management (managing and advising on approximately £11.8bn, primarily for institutional clients); and

AZIMUT asset management (specialised in asset management, the group offers financial advisory services for investors, primarily through its advisor networks).

Following the 36% price rally since the beginning of the year until May and the subsequent price correction, ÖWAG’s shares trade at a premium to the peer group on P/E and EV/EBITDA for FY18e of 28% and 37%, respectively. The premium widens in FY19e due to limited earnings growth expectations (9–10% per annum) as per Bloomberg consensus estimates. However, ÖWAG’s earnings growth may differ significantly from current market consensus, given that it is largely driven by performance fees based on the high-watermark approach. Moreover, Bloomberg consensus is currently based only on estimates of a single analyst. Importantly, a potential negative factor to take into account in a peer comparison is that ÖWAG’s listed shares are non-voting preference shares, while the non-listed voting stock is in the hands of management and selected employees.

Exhibit 3: Peer group comparison

 

Market cap

P/E (x)

EV/EBITDA (x)

Dividend yield (%)

 

(€m)

2018e

2019e

2020e

2018e

2019e

2020e

2018e

2019e

2020e

MLP

605.7

17.3

15.6

14.2

20.5

18.7

17.2

3.9%

4.3%

4.8%

Patrizia Immobilien

1,680.80

22.9

17.1

15.9

16.6

12.9

11.8

2.0%

2.7%

3.1%

IMPAX

284.3

19.3

18.3

17.3

N/A 

N/A 

N/A 

1.8%

2.2%

2.3%

AZIMUT

1,942.50

13.2

11.1

10.5

6.6

5.8

6

7.9%

8.8%

9.2%

Peer group average

 

18.2

15.5

14.5

14.5

12.5

11.7

3.9%

4.5%

4.8%

Ökoworld

121.1

23.2

21.2

19.3

20.0

18.3

16.7

3.5%

3.5%

3.5%

Premium to peer group

 

27.6%

36.3%

33.2%

37.4%

46.5%

43.6%

-10.8%

-22.1%

-27.7%

Source: ÖKOWORLD AG accounts, Bloomberg. Note: ÖWAG consensus is based on the estimates of a single analyst.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Any Information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors.

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Private: ÖKOWORLD

View All

Latest from the Financials sector

View All Financials content

Research: Healthcare

Acacia Pharma — Raising the BAR in PONV

Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). We expect FDA approval of Acacia’s lead product, BARHEMSYS (repurposed amisulpride), for the management of PONV by its 5 October 2018 PDUFA date. In the near term, Acacia will concentrate on the US commercial opportunity by expanding its sales and marketing infrastructure. We anticipate US launch of BARHEMSYS in Q219 for PONV ‘rescue treatment’ and expect broadening of use for PONV prophylaxis in subsequent years. We value Acacia Pharma at €579m or €10.9 per share.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free